News Related to Helus Pharma

Nature Medicine Publishes Helus Pharma's Phase 2a Trial of SPL026 for Major Depression

Jun 11, 2026

Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.

Compass Pathways' psilocybin data lifts psychedelic drug stocks

Apr 20, 2026

Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.

DMT Shows Rapid Antidepressant Effects in Phase 2 Trial for Major Depression

Feb 23, 2026

A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.

Psychedelic Therapies Advance in Depression Trials with Mixed Results

Feb 17, 2026

Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.